Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label multicenter study of SY-5007 in RET fusion-positive advanced non-small cell lung cancer
CTR20232014Phase 3Active
- Sponsor
- Shouyao Holdings
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sotetinib in non-small cell lung cancer (NSCLC), sponsored by Shouyao Holdings. Started Oct 2023; status: active.
02
Drugs
sotetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20232014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232014.